Semaglutide (GLP-1 receptor agonist) has emerged as the most significant advance in weight management medicine in decades. For women, who face unique metabolic challenges including polycystic ovary syndrome (PCOS), hormonal weight gain during perimenopause, and the metabolic consequences of estrogen decline, Semaglutide offers a mechanism-based approach to metabolic health that goes far beyond simple caloric restriction.
The GLP-1 Mechanism in Female Physiology
GLP-1 (glucagon-like peptide-1) receptors are expressed throughout the female reproductive system, including in the ovaries, uterus, and hypothalamic-pituitary axis. This means Semaglutide's effects in women extend beyond appetite regulation and glucose control — it directly interacts with the hormonal systems that govern female metabolic health.
PCOS and Insulin Resistance
PCOS affects approximately 10% of women of reproductive age and is characterized by insulin resistance, hyperandrogenism, and irregular menstrual cycles. Semaglutide addresses the root cause of PCOS-related metabolic dysfunction by improving insulin sensitivity, reducing circulating androgens, and promoting weight loss — all of which can restore menstrual regularity and improve fertility outcomes.
Perimenopause and Menopause
The hormonal changes of perimenopause — declining estrogen and progesterone — are associated with a significant shift in fat distribution from subcutaneous to visceral, increased insulin resistance, and reduced metabolic rate. Semaglutide directly counteracts these changes by targeting visceral fat preferentially and improving insulin signaling.